Halozyme Therapeutics Inc (HALO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Halozyme Therapeutics Inc stock (HALO) is currently trading at $63.24. Halozyme Therapeutics Inc PE ratio is 24.23. Halozyme Therapeutics Inc PS ratio (Price-to-Sales) is 5.24. Analyst consensus price target for HALO is $84.50. WallStSmart rates HALO as Moderate Buy.
- HALO PE ratio analysis and historical PE chart
- HALO PS ratio (Price-to-Sales) history and trend
- HALO intrinsic value — DCF, Graham Number, EPV models
- HALO stock price prediction 2025 2026 2027 2028 2029 2030
- HALO fair value vs current price
- HALO insider transactions and insider buying
- Is HALO undervalued or overvalued?
- Halozyme Therapeutics Inc financial analysis — revenue, earnings, cash flow
- HALO Piotroski F-Score and Altman Z-Score
- HALO analyst price target and Smart Rating
Halozyme Therapeutics Inc
📊 No data available
Try selecting a different time range
HALO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Halozyme Therapeutics Inc (HALO)
HALO trades at a significant discount to its Graham intrinsic value of $119.81, offering a 34% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Halozyme Therapeutics Inc (HALO) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, revenue growth. Concerns around peg ratio and price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
Halozyme Therapeutics Inc (HALO) Key Strengths (7)
Every $100 of shareholder equity generates $154 in profit
Keeps $56 of every $100 in revenue after operating costs
Revenue surging 51.60% year-over-year
Earnings per share surging 36.20% year-over-year
Keeps $23 of every $100 in revenue as net profit
108.05% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Halozyme Therapeutics Inc (HALO) Areas to Watch (3)
PEG ratio is negative or unavailable
Very expensive at 153.3x book value
Premium valuation at 5.2x annual revenue
Supporting Valuation Data
Halozyme Therapeutics Inc (HALO) Detailed Analysis Report
Overall Assessment
This company scores 70/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 7 register as strengths (avg 9.6/10) while 3 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with Return on Equity at 153.60%, Operating Margin at 56.30%, Profit Margin at 22.70%. Growth metrics are encouraging with Revenue Growth at 51.60%, EPS Growth at 36.20%.
The Bear Case
The primary concerns are PEG Ratio, Price/Book, Price/Sales. Some valuation metrics including PEG Ratio (N/A), Price/Sales (5.24), Price/Book (153.35) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 153.60% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 51.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Return on Equity and Operating Margin makes a compelling case at current levels. The key risk is PEG Ratio, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HALO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HALO's Price-to-Sales ratio of 5.24x trades at a deep discount to its historical average of 251.66x (0th percentile). The current valuation is 100% below its historical high of 7468.31x set in Dec 2006, and 0% above its historical low of 5.24x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~5.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Halozyme Therapeutics Inc (HALO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Halozyme Therapeutics Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 1.4B with 52% growth year-over-year. Profit margins are strong at 22.7%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 52% YoY, reaching 1.4B. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 15360.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Halozyme Therapeutics Inc maintain 52%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Halozyme Therapeutics Inc.
Bottom Line
Halozyme Therapeutics Inc offers an attractive blend of growth (52% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Halozyme Therapeutics Inc(HALO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.